The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Alectinib versus Crizotinib in Untreated ALK -Positive Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lung cancer (NSCLC). We investigated alectinib as compared with crizotinib in patients with previously untreated, advanced ALK-positive NSCLC, including those with asymptomatic CNS disease. METHODS: In a randomized, open-label, phase 3 trial, we randomly assigned 303 patients with previously untreated, advanced ALK-positive NSCLC to receive either alectinib (600 mg twice daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival. Secondary end points were independent review committee-assessed progression-free survival, time to CNS progression, objective response rate, and overall survival. RESULTS: During a median follow-up of 17.6 months (crizotinib) and 18.6 months (alectinib), an event of disease progression or death occurred in 62 of 152 patients (41%) in the alectinib group and 102 of 151 patients (68%) in the crizotinib group. The rate of investigator-assessed progression-free survival was significantly higher with alectinib than with crizotinib (12-month event-free survival rate, 68.4% [95% confidence interval (CI), 61.0 to 75.9] with alectinib vs. 48.7% [95% CI, 40.4 to 56.9] with crizotinib; hazard ratio for disease progression or death, 0.47 [95% CI, 0.34 to 0.65]; P<0.001); the median progression-free survival with alectinib was not reached. The results for independent review committee-assessed progression-free survival were consistent with those for the primary end point. A total of 18 patients (12%) in the alectinib group had an event of CNS progression, as compared with 68 patients (45%) in the crizotinib group (cause-specific hazard ratio, 0.16; 95% CI, 0.10 to 0.28; P<0.001). A response occurred in 126 patients in the alectinib group (response rate, 82.9%; 95% CI, 76.0 to 88.5) and in 114 patients in the crizotinib group (response rate, 75.5%; 95% CI, 67.8 to 82.1) (P=0.09). Grade 3 to 5 adverse events were less frequent with alectinib (41% vs. 50% with crizotinib). CONCLUSIONS: As compared with crizotinib, alectinib showed superior efficacy and lower toxicity in primary treatment of ALK-positive NSCLC. (Funded by F. Hoffmann-La Roche; ALEX ClinicalTrials.gov number, NCT02075840 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Even more variable are duration of response to targeted therapy, progression-free survival and overall survival16–26, 28–32, 35.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
In the citing paper
“both the rarity of co-drivers and strong addiction to the ALK fusion oncoprotein may account for the long progression-free survival observed in patients with ALK-rearrangements with the potent and selective second and third generation ALK inhibitors alectinib, brigatinib and lorlatinib23, 26, 27.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Self-citationGainor, J. F., Dardaei, L., Yoda, S., Friboulet, L., Leshchiner, I., Katayama, R., Dagogo‐Jack, I., Gadgeel, S. M., Schultz, K. R., Singh, M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0596 · Cited by 1,180
Self-citationSoria, J.-C., Tan, D. S. W., Chiari, R., Wu, Y.-L., Paz-Ares, L., Wolf, J., Geater, S. L., Orlov, S., Cortinovis, D., Yu, C.-J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30123-x · Cited by 1,151
Hida, T., Nokihara, H., Kondo, M., Kim, Y. H., Azuma, K., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Imamura, F., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30565-2 · Cited by 935
Gadgeel, S. M., Gandhi, L., Riely, G. J., Chiappori, A., West, H., Azada, M. C., Morcos, P. N., Lee, R.-M., Garcia, L., Yu, L. J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70362-6 · Cited by 709
Self-citationShaw, A. T., Gandhi, L., Gadgeel, S., Riely, G. J., Cetnar, J., West, H., Camidge, D. R., Socinski, M. A., Chiappori, A., Mekhail, T., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00488-x · Cited by 638
Self-citationOu, S. I., Ahn, J. S., Petris, L. D., Govindan, R., Yang, J. C., Hughes, B. G. M., Léna, H., Moro‐Sibilot, D., Bearz, A., Viteri, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.9443 · Cited by 592
Self-citationBrain metastases in patients with EGFR -mutated or ALK -rearranged non-small-cell lung cancers
Rangachari, D., Yamaguchi, N., VanderLaan, P. A., Folch, E. E., Mahadevan, A., Floyd, S., Uhlmann, E. J., Wong, E. T., Dahlberg, S. E., Huberman, M. S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.01.020 · Cited by 547
Katayama, R., Lovly, C. M., & Shaw, A. T. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2791 · Cited by 265
Self-citationALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
Awad, M. M., & Shaw, A. T. (2014) · PubMed · Cited by 245
Self-citation
Flagged first, then by citations
Research works printed but not linked: 3
- Awad MM, 2014, Clin Adv Hematol Oncol, 12, 429
- Lu S, 2016, J Clin Oncol
- Hida T, Lancet
Cited by
Sorted by citations
Items 801–900 of 1,000
Review of the diagnosis and treatment of brain metastases
Narita, Y., Sato, S., & Kayama, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab182 · Cited by 18
Oligometastatic Non-Small Cell Lung Cancer: A Practical Review of Prospective Trials
Baydoun, A., Lee, V. L., & Biswas, T. (2022) · Cancers · doi:10.3390/cancers14215339 · Cited by 18
A multidisciplinary management algorithm for brain metastases
Ramos, A. D., Giantini-Larsen, A., Pannullo, S. C., Brandmaier, A., Knisely, J. P. S., Magge, R., Wilcox, J. A., Pavlick, A. C., Ma, B., Pisapia, D. J., et al. (2022) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdac176 · Cited by 18
Variation in Use of Lung Cancer Targeted Therapies Across State Medicaid Programs, 2020-2021
Roberts, T. J., Kesselheim, A. S., & Avorn, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.52562 · Cited by 18
Noh, K., Yi, S., Kim, H.-R., Lee, J. E., Kim, S., Yoo, W., Jung, E., Choi, J., Park, H., Hwang, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02301-z · Cited by 17
The 2024 International Association for the Study of Lung Cancer Global Survey on Biomarker Testing
Smeltzer, M. P., King, J. C., Connolly, C., Brunson, K., Chau, M., Chen, S., Kerpel-Fronius, A., Lantuéjoul, S., Mohan, A., Plaxco, A. P., et al. (2025) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2025.07.114 · Cited by 17
Seto, T., Hayashi, H., Satouchi, M., Goto, Y., Niho, S., Nogami, N., Hida, T., Takahashi, T., Sakakibara‐Konishi, J., Morise, M., et al. (2020) · Cancer Science · doi:10.1111/cas.14576 · Cited by 17
Novel Multitarget Therapies for Lung Cancer and Respiratory Disease
Yumura, M., Nagano, T., & Nishimura, Y. (2020) · Molecules · doi:10.3390/molecules25173987 · Cited by 17
Spatial profiling technologies and applications for brain cancers
Croft, P. K., Sadeghirad, H., Gasper, H. M., O'Byrne, K. J., Lakhani, S. R., & Kulasinghe, A. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1900735 · Cited by 18
Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
Benjamin, D. J., Haslam, A., Gill, J., & Prasad, V. K. (2022) · Cancer Medicine · doi:10.1002/cam4.4703 · Cited by 17
Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis
Wen, Y., Jiang, T., Wu, X., Peng, H., Ren, S., & Zhou, C. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221116607 · Cited by 17
Silibinin Overcomes EMT-Driven Lung Cancer Resistance to New-Generation ALK Inhibitors
Verdura, S., Encinar, J. A., Teixidor, E., Segura‐Carretero, A., Micol, V., Cuyàs, E., Bosch‐Barrera, J., & Menéndez, J. A. (2022) · Cancers · doi:10.3390/cancers14246101 · Cited by 18
Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure
Fukuda, A., & Yoshida, T. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2265566 · Cited by 18
Khasraw, M., Yalamanchili, P., Santhanagopal, A., Wu, C., Salas, M., Meng, J., Karnoub, M., Esker, S., & Felip, E. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02799-9 · Cited by 19
Arriola, E., de Castro, J., García-Campelo, R., Bernárdez, B., Bernabé, R., Bruna, J., Dómine, M., Isla, D., Juan, Ó., López‐Fernández, T., et al. (2024) · Clinical Drug Investigation · doi:10.1007/s40261-024-01379-7 · Cited by 17
Bauman, J. R., Liu, G., Preeshagul, I. R., Liu, S. V., Melosky, B. L., Abrahami, D., Li, B. C., Thomaidou, D., Duncan, K., Krulewicz, S., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107919 · Cited by 17
Challenges and prospects in utilizing technologies for gene fusion analysis in cancer diagnostics
Su, X., Zheng, Q., Xiu, X., Zhao, Q., Wang, Y., Han, D. W., & Song, P. (2024) · Med-X · doi:10.1007/s44258-024-00033-3 · Cited by 17
Cordani, N., Nova, D., Sala, L., Abbate, M. I., Colonese, F., Cortinovis, D. L., & Canova, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011214 · Cited by 18
Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges
Lim, J. U., Jung, J., Kim, Y. W., Kim, C. Y., Lee, S. H., Park, D. W., Choi, S. I., Ji, W., Yeo, C. D., & Lee, S. H. (2025) · Biomedicines · doi:10.3390/biomedicines13020470 · Cited by 20
Quantitative Bias Analysis for Single-Arm Trials With External Control Arms
Gupta, A., Hsu, G. G., Kent, S., Duffield, S. J., Merinopoulou, E., Lockhart, A., Arora, P., Ray, J. A., Wilkinson, S., Scheuer, N., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.2152 · Cited by 17
Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy
Peters, S., & Zimmermann, S. (2018) · Current Treatment Options in Oncology · doi:10.1007/s11864-018-0553-x · Cited by 17
Self-citationDriver mutations of young lung adenocarcinoma patients with malignant pleural effusion
Wu, S., Liu, Y., Yu, C., Yang, J. C., & Shih, J. (2018) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22647 · Cited by 18
Safety and Tolerability of Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer
Rocco, D., Battiloro, C., Gravara, L. D., & Gridelli, C. (2019) · Drug Safety · doi:10.1007/s40264-018-0771-y · Cited by 17
Seetasith, A., Wong, W. B., Tse, J. Y. M., & Burudpakdee, C. (2019) · Journal of Medical Economics · doi:10.1080/13696998.2019.1580200 · Cited by 17
Treatment of Refractory ALK Rearranged Anaplastic Large Cell Lymphoma With Alectinib
Reed, D. R., Hall, R. D., Gentzler, R. D., Volodin, L., Douvas, M. G., & Portell, C. A. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.03.001 · Cited by 17
Bedas, A., Peled, N., Rabinovich, N. M., Mishaeli, M., Shochat, T., Zer, A., Rotem, O., Allen, A. M., Bar, J., Dudnik, E., et al. (2019) · Oncology Research and Treatment · doi:10.1159/000499086 · Cited by 17
Gafer, H., de Waard, Q., Compter, A., & van den Heuvel, M. M. (2019) · BMJ Case Reports · doi:10.1136/bcr-2018-227299 · Cited by 19
Lorlatinib for the treatment of ALK-positive metastatic non-small cell lung cancer
Choo, J. R.-E., & Soo, R. A. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1744438 · Cited by 17
Li, M., Hou, X., Zhou, C., Feng, W., Jiang, G., Long, H., Yang, S., Chen, J., Wang, N., Wang, K., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01216 · Cited by 17
Ueda, S., Shukuya, T., Hayashi, T., Suzuki, M., Kondo, A., Arai, Y., Takeshige, T., Ninomiya, H., & Takahashi, K. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13829 · Cited by 17
Kuzich, J. A., Heynemann, S., Geoghegan, N. D., Evelyn, C., O'Mahoney, S., Wilson, S., Campbell, J., Rogers, K. L., Solomon, B., Westerman, D., et al. (2021) · Pathology · doi:10.1016/j.pathol.2020.10.023 · Cited by 17
Li, S., Li, J., Peng, L., Li, Y., & Wan, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684073 · Cited by 17
Kano, H., Ichihara, E., Watanabe, H., Nishii, K., Ando, C., Nakasuka, T., Ninomiya, K., Kato, Y., Kubo, T., Rai, K., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0965 · Cited by 17
Carnevale, J. A., Imber, B. S., Winston, G. M., Goldberg, J. L., Ballangrud, Å., Brennan, C., Beal, K. P., Tabar, V. S., & Moss, N. S. (2021) · Journal of neurosurgery · doi:10.3171/2021.3.jns204347 · Cited by 17
Methods for Actionable Gene Fusion Detection in Lung Cancer: Now and in the Future
Pisapia, P., Pepe, F., Sgariglia, R., Nacchio, M., Russo, G., Gragnano, G., Conticelli, F., Salatiello, M., Luca, C. D., Girolami, I., et al. (2021) · Pharmacogenomics · doi:10.2217/pgs-2021-0048 · Cited by 17
Gu, R., Shi, Z., Duan, T., & Song, M. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s334213 · Cited by 17
Alternative Treatment Options to ALK Inhibitor Monotherapy for EML4-ALK-Driven Lung Cancer
Papageorgiou, S., Pashley, S. L., O’Regan, L., Khan, S., Bayliss, R. W., & Fry, A. M. (2022) · Cancers · doi:10.3390/cancers14143452 · Cited by 17
Jiang, J., Zhao, C., Zhang, F., Liu, Z., Zhou, K., Ren, X., & Wan, Y. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060782 · Cited by 17
Sridharan, V., Neyaz, A., Chogule, A., Baiev, I., Reyes, S., Fritcher, E. G. B., Lennerz, J. K., Sukov, W. R., Kipp, B. R., Ting, D. T., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1244 · Cited by 17
Hunt, A. L., Nutcharoen, A., Randall, J., Papazian, A., Deeken, J. F., Maxwell, G. L., Bateman, N. W., Petricoin, E. F., Benyounes, A., Conrads, T. P., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad129 · Cited by 17
Chu, P., Antoniou, M., Bhutani, M. K., Aziez, A., & Daigl, M. (2020) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2020-0063 · Cited by 17
Bai, F., Qu, Z., Yan, J., Zhang, H. W., Xu, J., Ye, M. M., Wu, H. L., Liao, X. G., & Shen, D. L. (2001) · PubMed · Cited by 17
Jamme, P., Descarpentries, C., Gervais, R., Dansin, É., Wislez, M., Grégoire, V., Richard, N., Baldacci, S., Rabbe, N., Kyheng, M., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.013 · Cited by 17
Treatment of oncogene-driven non-small cell lung cancer
Kastelijn, E. A., Langen, A. J. D., & Peters, B. J. M. (2019) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000572 · Cited by 16
Challenges of the phase I drug development in non-small cell lung cancer
Lin, C. (2019) · Chinese Clinical Oncology · doi:10.21037/cco.2019.06.03 · Cited by 16
Evaluating larotrectinib for the treatment of advanced solid tumors harboring an NTRK gene fusion
Filippi, R., Depetris, I., & Satolli, M. A. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1876664 · Cited by 17
Dong, O. M., Poonnen, P. J., Winski, D., Reed, S. D., Vashistha, V., Bates, J. S., Kelley, M. J., & Voora, D. (2021) · Value in Health · doi:10.1016/j.jval.2021.09.017 · Cited by 16
The Blood-Brain Barrier: Implications for Experimental Cancer Therapeutics
Straehla, J. P., Reardon, D. A., Wen, P. Y., & Agar, N. Y. R. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-040433 · Cited by 17
Off-Target Effects of Cancer Therapy on Development of Therapy-Induced Arrhythmia: A Review
Leiva, O., Bohart, I., Ahuja, T., & Park, D. S. (2023) · Cardiology · doi:10.1159/000529260 · Cited by 17
Genomics-Driven Precision Medicine in Pediatric Solid Tumors
Suthapot, P., Chiangjong, W., Chaiyawat, P., Choochuen, P., Pruksakorn, D., Sangkhathat, S., Hongeng, S., Anurathapan, U., & Chutipongtanate, S. (2023) · Cancers · doi:10.3390/cancers15051418 · Cited by 17
Schenk, E. L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-883 · Cited by 18
NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know
Mitchell, C. L., Zhang, A. L., Bruno, D. S., & Almeida, F. A. (2023) · Diagnostics · doi:10.3390/diagnostics13061117 · Cited by 16
Lanser, D. A. C., de Leeuw, S. P., Hoop, E. O., de Bruijn, P., Paats, M. S., Dumoulin, D. W., Koolen, S. L. W., Dingemans, A. C., Mathijssen, R. H. J., & Veerman, G. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.7017 · Cited by 16
Management of Brain Metastases: A Review of Novel Therapies
Bellur, S. S., Khosla, A. A., Ozair, A., Kotecha, R. R., McDermott, M. W., & Ahluwalia, M. S. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1776782 · Cited by 16
Tyrosine kinase inhibitors in cancers: Treatment optimization – Part I
Combarel, D., Dousset, L., Bouchet, S., Ferrer, F., Tétu, P., Lebbé, C., Ciccolini, J., Meyer, N., & Paci, A. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104384 · Cited by 16
Development of brain metastases in non-small-cell lung cancer: high-risk features
Winslow, N., Boyle, J. A., Miller, W., Wang, Y. A., Geoffroy, F. J., & Tsung, A. J. (2024) · CNS Oncology · doi:10.1080/20450907.2024.2395804 · Cited by 16
Davies, J., Martinec, M., Coudert, M., Delmar, P., & Crane, G. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1533458 · Cited by 16
Physiology, Tyrosine Kinase Receptors
Wintheiser, G. A., & Silberstein, P. T. (2019) · StatPearls · Cited by 16
An HPLC–PDA method for determination of alectinib concentrations in the plasma of an adolescent
Lee, S., Nath, C. E., Balzer, B. W. R., Lewis, C. R., Trahair, T. N., Anazodo, A. C., & Shaw, P. J. (2019) · Acta Chromatographica · doi:10.1556/1326.2019.00578 · Cited by 16
cMyc and ERK activity are associated with resistance to ALK inhibitory treatment in glioblastoma
Berberich, A., Schmitt, L.-M., Pusch, S., Hielscher, T., Rübmann, P., Hucke, N., Latzer, P., Heßling, B., Lemke, D., Keßler, T., et al. (2019) · Journal of Neuro-Oncology · doi:10.1007/s11060-019-03348-z · Cited by 16
Huang, J.-R., Chou, C.-W., & Chao, H. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220961557 · Cited by 16
Jünger, S. T., Schödel, P., Ruess, D. F., Ruge, M. I., Brand, J.-S., Wittersheim, M., Eich, M., Schmidt, N. O., Goldbrunner, R., Grau, S., et al. (2020) · Cancers · doi:10.3390/cancers12123618 · Cited by 16
Gullapalli, V., Xu, W., Lewis, C. R., Anazodo, A. C., & Kidson‐Gerber, G. (2021) · Journal of Hematopathology · doi:10.1007/s12308-020-00427-3 · Cited by 16
Yasuma, T., Toda, M., Kobori, H., Tada, N., D’Alessandro‐Gabazza, C. N., & Gabazza, E. C. (2021) · Journal of Fungi · doi:10.3390/jof7080590 · Cited by 16
Hsu, J., Jaminion, F., Guerini, E., Balas, B. I., Bordogna, W., Morcos, P. N., & Frey, N. (2021) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12702 · Cited by 16
Self-citationZeng, Q., Zhang, X., He, S., Zhou, Z., Xia, L., Zhang, W., & Zeng, L. (2021) · Chemotherapy · doi:10.1159/000521452 · Cited by 16
Chen, J., Chen, Y., Liu, L., Jin, X., Shen, Z., Chen, W., Yang, T., Xu, S., Wang, G., Cheng, Y., et al. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17094 · Cited by 17
Lin, H. M., Wu, Y., Yin, Y., Niu, H., Curran, E. A., Lovly, C. M., & Humphries, M. J. (2022) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.09.010 · Cited by 16
Xia, G., Huang, J., Ni, J., Song, M., Zhang, J., Hofman, P. M., Christopoulos, P., Grenda, A., & Huang, M. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-154 · Cited by 16
Melosky, B. L., Cheema, P. K., Agulnik, J. S., Albadine, R., Bebb, D. G., Blais, N., Burkes, R. L., Butts, C. A., Card, P. B., Chan, A. M. Y., et al. (2018) · Current Oncology · doi:10.3747/co.25.4379 · Cited by 16
KOYAMA, K., Katsurada, N., Jimbo, N., TACHIHARA, M. Y., Tamura, D., Nakata, K., Nagano, T., Yamamoto, M., Kamiryo, H., Kobayashi, K., et al. (2019) · Pathology International · doi:10.1111/pin.12782 · Cited by 16
McKeage, M. J., Tin, S. T., Khwaounjoo, P., Sheath, K. L., Dixon‐McIver, A., Ng, D., Sullivan, R., Cameron, L., Shepherd, P., Laking, G. R., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14435 · Cited by 16
Russo, A., Cardona, A. F., Caglevic, C., Manca, P., Ruíz-Patiño, A., Arrieta, O. G., & Rolfo, C. D. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr-2019-cnsclc-06 · Cited by 16
Ensartinib (X-396): what does it add for patients with ALK-rearranged NSCLC
Li, T., Ma, W., & Tian, E. C. (2018) · Chinese Clinical Oncology · doi:10.21037/cco.2018.10.12 · Cited by 16
The evolving landscape of brain metastasis: volume II
Valiente, M., Anders, C. K., Boire, A. A., Izar, B., Kotecki, N., Malladi, S., Massagué, J., Moss, N. S., Neman, J., Preusser, M., et al. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.11.007 · Cited by 16
Zhou, C., Lu, Y., Kim, S., Reungwetwattana, T., Zhou, J., Zhang, Y., He, J., Yang, J., Cheng, Y., Lee, S., et al. (2024) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2024.100700 · Cited by 15
Swalduz, A., Schiffler, C., Curcio, H., Ambasager, B., Moel, G. L., Debieuvre, D., Dot, J.-M., Duruisseaux, M., Fournel, P., Odier, L., et al. (2024) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2024.12.011 · Cited by 15
Jain, R., & Chen, H. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s126507 · Cited by 15
Singhi, E. K., & Horn, L. (2018) · Future Oncology · doi:10.2217/fon-2017-0619 · Cited by 15
Huang, X. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0707-5 · Cited by 15
Costa, D. B. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy339 · Cited by 15
Lee, Y.-C., Hsieh, C.-C., Lee, Y.-L., & Li, C. (2019) · Medicina · doi:10.3390/medicina55020029 · Cited by 15
Irie, H., Ito, K., Fujioka, Y., Oguchi, K., Fujioka, A., Hashimoto, A., Ohsawa, H., Tanaka, K. F., Funabashi, K., Araki, H., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1085 · Cited by 15
Iwama, E., Goto, Y., Murakami, H., Tsumura, S., Sakashita, H., Mori, Y., Nakagaki, N., Fujita, Y., Seike, M., Bessho, A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0728 · Cited by 15
Nogová, L., Mattonet, C., Scheffler, M., Taubert, M., Gardizi, M., Sos, M. L., Michels, S. Y. F., Fischer, R. N., Limburg, M., Abdulla, D. S. Y., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3131 · Cited by 15
Popat, S., Liu, G., Lü, S., Song, G. C., Ma, X., & Yang, J. C. (2021) · Future Oncology · doi:10.2217/fon-2021-0608 · Cited by 15
A call to action: molecular pathology in Brazil
da Cunha, I. W., Coudry, R. D. A., de Macêdo, M. P., de Assis, E. A. C. P., Stefani, S. D., & Soares, F. A. (2021) · Surgical and Experimental Pathology · doi:10.1186/s42047-021-00096-1 · Cited by 15
Gaule, M., Pesoni, C., Quinzii, A., Zecchetto, C., Casalino, S., Merz, V., Contarelli, S., Pietrobono, S., Vissio, E., Molinaro, L., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00400 · Cited by 15
Santoro, A., Su, W., Navarro, A., Simonelli, M., Yang, J. C., Ardizzoni, A., Barlési, F., Kang, J., DiDominick, S., Abdelhady, A. M., et al. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.02.010 · Cited by 15
Yanagimura, N., Takeuchi, S., Fukuda, K., Arai, S., Tanimoto, A., Nishiyama, A., Ogo, N., Takahashi, H., Asai, A., Watanabe, S., et al. (2022) · npj Precision Oncology · doi:10.1038/s41698-022-00254-y · Cited by 16
Intracranial Metastatic Disease: Present Challenges, Future Opportunities
Li, A. Y., Gaebe, K., Jerzak, K. J., Cheema, P. K., Sahgal, A., & Das, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.855182 · Cited by 16
Kunz, J., Wiedemann, C., Grosch, H., Kriegsmann, K., Gryzik, S., Felden, J., Hundemer, M., Seker‐Cin, H., Stenzinger, M., Leo, A., et al. (2022) · Cancers · doi:10.3390/cancers14112720 · Cited by 15
Lee, H., Krishnan, V., Wirth, L. J., Nucera, C., Venturina, M., Sadow, P. M., Mita, A. C., & Sacks, W. L. (2022) · Thyroid · doi:10.1089/thy.2022.0389 · Cited by 15
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Iwama, E., Nakanishi, Y., & Okamoto, I. (2018) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2018.1432356 · Cited by 15
Oncogene Addicted Non-Small-Cell Lung Cancer: Current Standard and Hot Topics
Vecchiarelli, S., & Bennati, C. (2018) · Future Oncology · doi:10.2217/fon-2018-0095 · Cited by 17
Redefining Treatment Paradigms in First-line Advanced Non–Small-Cell Lung Cancer
Heigener, D. F., Kerr, K. M., Laing, G. M., Mok, T. S. K., Moiseyenko, F. V., & Reck, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1894 · Cited by 16
Self-citationMoldaver, D., Hurry, M. V., Evans, W. K., Cheema, P. K., Sangha, R. S., Burkes, R. L., Melosky, B. L., Tran, D., Boehm, D., Venkatesh, J., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.019 · Cited by 15
Lorlatinib and Bevacizumab Activity inALK-Rearranged Lung Cancers After Lorlatinib Progression
Choudhury, N. J., Young, R. J., Sellitti, M. J., Miller, A. M., & Drilon, A. E. D. C. (2020) · JCO Precision Oncology · doi:10.1200/po.20.00271 · Cited by 15
Leptomeningeal metastases from non-small cell lung cancer: state of the art and recent advances
Pellerino, A., Internò, V., Muscolino, E., Mo, F., Bruno, F., Pronello, E., Franchino, F., Soffietti, R., & Rudà, R. (2020) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2020.80 · Cited by 15
Metadata
- Authors
- Peters, S., Camidge, D. R., Shaw, A. T., Gadgeel, S., Ahn, J. S., Kim, D.-W., Ou, S.-H. I., Pérol, M., Dziadziuszko, R., Rosell, R., Zeaiter, A., Mitry, E., Golding, S., Balas, B., Noe, J., Morcos, P. N., & Mok, T.
- Affiliations
- F. Hoffmann-La Roche AG (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-08-31
- Volume
- 377
- Issue
- 9
- Pages
- 829-838
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2624310346
- Cited by
- 2,527
- References
- 14
- Citations by year
- 2026: 173 · 2025: 216 · 2024: 260 · 2023: 270 · 2022: 306 · 2021: 336 · 2020: 327 · 2019: 276 · 2018: 277 · 2017: 82
- FWCI
- 218.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- SERVAL (Université de Lausanne) (publishedVersion, other-oa)
- Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) (submittedVersion, public-domain)
- IRIS (submittedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, public-domain)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Ariad Pharmaceuticals
- Celgene
- F. Hoffmann-La Roche
- Array BioPharma
- Regeneron Pharmaceuticals
- Taiho Pharmaceutical
- Les Laboratories Pierre Fabre
- Clovis Oncology
- G1 Therapeutics
- Eisai
- Genentech
- EMD Serono
- Ignyta
- Loxo Oncology
- Foundation Medicine
- Daiichi Sankyo Europe
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- alectinib, crizotinib, anaplastic lymphoma kinase, ALK-positive non-small cell lung cancer, ALK inhibitors, progression-free survival, CNS progression, central nervous system metastasis, objective response rate, overall survival, first-line therapy, targeted therapy, head-to-head comparison
- MeSH terms
- Crizotinib, Anaplastic Lymphoma Kinase, Adult, Aged, 80 and over, Animals, Antineoplastic Agents, Carbazoles, Carcinoma, Non-Small-Cell Lung, Female, Follow-Up Studies, Humans, Lung Neoplasms, Male, Middle Aged, Piperidines, Pyrazoles, Pyridines, Central Nervous System Neoplasms, Disease-Free Survival, Receptor Protein-Tyrosine Kinases, Protein Kinase Inhibitors, Kaplan-Meier Estimate, Young Adult, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
